{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:17:33Z","timestamp":1790727453172,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Diabetic retinopathy (DR) is a progressive retinal disease that leads to vision loss if not detected early. Metabolomic analysis of vitreous humor offers a promising approach to identifying biomarkers associated with disease onset and progression. This pilot study investigates the metabolomic profiles of vitreous humor from patients at different stages of DR, aiming to uncover potential biomarkers for early detection and monitoring of disease progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Vitreous samples were collected during therapeutic pars plana vitrectomy of 23 patients without diabetes (CTRL), with diabetes and without retinopathy (DIA), non-proliferative DR (NPDR) and proliferative DR (PDR). Metabolomics was performed using high-performance liquid chromatography coupled with high-resolution mass spectrometry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Principal component analysis revealed distinct metabolic signatures differentiating the patient groups. Lysine, proline, and arginine levels progressively increased from DIA to NPDR and PDR stages, highlighting their association with disease progression. Methionine and threonine showed notable increases in PDR compared to all other groups, while carnitine, a key metabolite in lipid metabolism, exhibited stage-specific increases, peaking in PDR. The detection of systemic and topical drugs, including metformin and tropicamide, in the vitreous further emphasizes altered ocular permeability in DR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our findings suggest that metabolomic profiling could provide valuable insights into the underlying pathogenesis of DR and serve as a foundation for personalized therapeutic strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40942-025-00682-5","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T09:58:35Z","timestamp":1747907915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Metabolomic biomarkers in vitreous humor: unveiling the molecular landscape of diabetic retinopathy progression"],"prefix":"10.1186","volume":"11","author":[{"given":"John Kim","family":"Hiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise M\u00f8rk","family":"Sand\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Rootwelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja \u00d8steby","family":"Vassli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xhevat","family":"Lumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Carstens","family":"Moe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor Paaske","family":"Utheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja Benedikte Prest\u00f8","family":"Elgst\u00f8en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Petrovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"issue":"13","key":"682_CR1","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMra1005073","volume":"366","author":"DA Antonetti","year":"2012","unstructured":"Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227\u201339.","journal-title":"N Engl J Med"},{"issue":"09","key":"682_CR2","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1055\/s-0043-120570","volume":"126","author":"M Voigt","year":"2018","unstructured":"Voigt M, Schmidt S, Lehmann T, K\u00f6hler B, Kloos C, Voigt U, et al. Prevalence and progression rate of diabetic retinopathy in type 2 diabetes patients in correlation with the duration of diabetes. Exp Clin Endocrinol Diabetes. 2018;126(09):570\u20136.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"682_CR3","doi-asserted-by":"crossref","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2(1).","DOI":"10.1186\/s40662-015-0026-2"},{"issue":"9","key":"682_CR4","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2337\/dc15-2171","volume":"39","author":"JL Leasher","year":"2016","unstructured":"Leasher JL, Bourne RRA, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: A Meta-analysis from 1990 to 2010. Diabetes Care. 2016;39(9):1643\u20139.","journal-title":"Diabetes Care"},{"issue":"2","key":"682_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S2213-8587(18)30128-1","volume":"7","author":"C Sabanayagam","year":"2019","unstructured":"Sabanayagam C, Banu R, Chee ML, Lee R, Wang YX, Tan G, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol. 2019;7(2):140\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"682_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.survophthal.2018.04.003","volume":"63","author":"H Safi","year":"2018","unstructured":"Safi H, Safi S, Hafezi-Moghadam A, Ahmadieh H. Early detection of diabetic retinopathy. Surv Ophthalmol. 2018;63(5):601\u20138.","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"682_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2213-8587(19)30411-5","volume":"8","author":"S Vujosevic","year":"2020","unstructured":"Vujosevic S, Aldington SJ, Silva P, Henrn\u00e1ndez C, Scanlon P, Peto T, et al. Screening for diabetic retinopathy: new perspectives and challenges. Lancet Diabetes Endocrinol. 2020;8(4):337\u201347.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"682_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.preteyeres.2018.11.002","volume":"69","author":"\u00ce La\u00edns","year":"2019","unstructured":"La\u00edns \u00ce, Gantner M, Murinello S, Lasky-Su JA, Miller JW, Friedlander M, et al. Metabolomics in the study of retinal health and disease. Prog Retin Eye Res. 2019;69:57\u201379.","journal-title":"Prog Retin Eye Res"},{"issue":"8","key":"682_CR9","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1515\/CCLM.2011.638","volume":"49","author":"C Boulagnon","year":"2011","unstructured":"Boulagnon C, Garnotel R, Fornes P, Gillery P. Post-mortem biochemistry of vitreous humor and glucose metabolism: an update. Clin Chem Lab Med CCLM. 2011;49(8):1265\u201370.","journal-title":"Clin Chem Lab Med CCLM"},{"key":"682_CR10","doi-asserted-by":"crossref","unstructured":"Midena E, Frizziero L, Midena G, Pilotto E. Intraocular fluid biomarkers (liquid biopsy) in human diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2021.","DOI":"10.1007\/s00417-021-05285-y"},{"issue":"12","key":"682_CR11","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s13361-016-1469-y","volume":"27","author":"AC Schrimpe-Rutledge","year":"2016","unstructured":"Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, Mclean JA. Untargeted metabolomics Strategies\u2014Challenges and emerging directions. J Am Soc Mass Spectrom. 2016;27(12):1897\u2013905.","journal-title":"J Am Soc Mass Spectrom"},{"issue":"9","key":"682_CR12","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1167\/iovs.10-5348","volume":"51","author":"I Barba","year":"2010","unstructured":"Barba I, Garcia-Ram\u00edrez M, Hern\u00e1ndez C, Alonso MA, Masmiquel L, Garc\u00eda-Dorado D, et al. Metabolic fingerprints of proliferative diabetic retinopathy: an 1H-NMR-based metabonomic approach using vitreous humor. Invest Ophthalmol Vis Sci. 2010;51(9):4416\u201321.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"682_CR13","first-page":"15","volume":"12","author":"LP Paris","year":"2016","unstructured":"Paris LP, Johnson CH, Aguilar E, Usui Y, Cho K, Hoang LT, et al. Global metabolomics reveals metabolic dysregulation in ischemic retinopathy. Metabolomics Off J Metabolomic Soc. 2016;12:15.","journal-title":"Metabolomics Off J Metabolomic Soc"},{"key":"682_CR14","doi-asserted-by":"publisher","first-page":"41984","DOI":"10.1038\/srep41984","volume":"7","author":"H Kunikata","year":"2017","unstructured":"Kunikata H, Ida T, Sato K, Aizawa N, Sawa T, Tawarayama H, et al. Metabolomic profiling of reactive persulfides and polysulfides in the aqueous and vitreous humors. Sci Rep. 2017;7:41984.","journal-title":"Sci Rep"},{"issue":"7","key":"682_CR15","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1021\/acs.jproteome.8b00169","volume":"17","author":"NR Haines","year":"2018","unstructured":"Haines NR, Manoharan N, Olson JL, D\u2019Alessandro A, Reisz JA. Metabolomics analysis of human vitreous in diabetic retinopathy and rhegmatogenous retinal detachment. J Proteome Res. 2018;17(7):2421\u20137.","journal-title":"J Proteome Res"},{"issue":"1","key":"682_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00592-019-01363-0","volume":"57","author":"H Wang","year":"2020","unstructured":"Wang H, Fang J, Chen F, Sun Q, Xu X, Lin SH, et al. Metabolomic profile of diabetic retinopathy: a GC-TOFMS-based approach using vitreous and aqueous humor. Acta Diabetol. 2020;57(1):41\u201351.","journal-title":"Acta Diabetol"},{"key":"682_CR17","doi-asserted-by":"publisher","first-page":"108799","DOI":"10.1016\/j.exer.2021.108799","volume":"214","author":"T Zhao","year":"2022","unstructured":"Zhao T, Wang Y, Guo X, Li H, Jiang W, Xiao Y, et al. Altered Oxylipin levels in human vitreous indicate imbalance in pro-\/anti-inflammatory homeostasis in proliferative diabetic retinopathy. Exp Eye Res. 2022;214:108799.","journal-title":"Exp Eye Res"},{"issue":"8","key":"682_CR18","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1021\/acs.jproteome.1c00326","volume":"20","author":"HB Skogvold","year":"2021","unstructured":"Skogvold HB, Sand\u00e5s EM, \u00d8steby A, L\u00f8kken C, Rootwelt H, R\u00f8nning PO, et al. Bridging the Polar and hydrophobic metabolome in Single-Run untargeted liquid Chromatography-Mass spectrometry dried blood spot metabolomics for clinical purposes. J Proteome Res. 2021;20(8):4010\u201321.","journal-title":"J Proteome Res"},{"issue":"4","key":"682_CR19","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1021\/es5002105","volume":"48","author":"EL Schymanski","year":"2014","unstructured":"Schymanski EL, Jeon J, Gulde R, Fenner K, Ruff M, Singer HP, et al. Identifying small molecules via high resolution mass spectrometry: communicating confidence. Environ Sci Technol. 2014;48(4):2097\u20138.","journal-title":"Environ Sci Technol"},{"key":"682_CR20","doi-asserted-by":"publisher","first-page":"871291","DOI":"10.3389\/fmolb.2022.871291","volume":"9","author":"Z Wang","year":"2022","unstructured":"Wang Z, Tang J, Jin E, Zhong Y, Zhang L, Han X, et al. Serum untargeted metabolomics reveal potential biomarkers of progression of diabetic retinopathy in Asians. Front Mol Biosci. 2022;9:871291.","journal-title":"Front Mol Biosci"},{"key":"682_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.exer.2018.05.004","volume":"173","author":"S Vidhya","year":"2018","unstructured":"Vidhya S, Ramya R, Coral K, Sulochana KN, Bharathidevi SR. Free amino acids Hydroxyproline, lysine, and glycine promote differentiation of retinal pericytes to adipocytes: A protective role against proliferative diabetic retinopathy. Exp Eye Res. 2018;173:179\u201387.","journal-title":"Exp Eye Res"},{"issue":"3","key":"682_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jdiacomp.2015.12.009","volume":"30","author":"N Mishra","year":"2016","unstructured":"Mishra N, Saxena S, Shukla RK, Singh V, Meyer CH, Kruzliak P, et al. Association of serum N\u03b5-Carboxy Methyl lysine with severity of diabetic retinopathy. J Diabetes Complications. 2016;30(3):511\u20137.","journal-title":"J Diabetes Complications"},{"key":"682_CR23","doi-asserted-by":"publisher","first-page":"108880","DOI":"10.1016\/j.diabres.2021.108880","volume":"177","author":"L Ying","year":"2021","unstructured":"Ying L, Shen Y, Zhang Y, Wang Y, Liu Y, Yin J, et al. Association of advanced glycation end products with diabetic retinopathy in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2021;177:108880.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"682_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1262-3636(07)70006-X","volume":"29","author":"M Wautier","year":"2003","unstructured":"Wautier M, Massin P, Guillausseau P, Huijberts M, Levy B, Boulanger E, et al. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab. 2003;29(1):44\u201352.","journal-title":"Diabetes Metab"},{"issue":"8","key":"682_CR25","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1007\/s00125-004-1455-y","volume":"47","author":"BO Boehm","year":"2004","unstructured":"Boehm BO, Schilling S, Rosinger S, Lang GE, Lang GK, Kientsch-Engel R, et al. Elevated serum levels of N\u03b5-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia. 2004;47(8):1376\u20139.","journal-title":"Diabetologia"},{"issue":"5","key":"682_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1056-8727(99)00052-5","volume":"13","author":"N Tamamo\u011fullari","year":"1999","unstructured":"Tamamo\u011fullari N, Sili\u011f Y, \u0130\u00e7a\u011fasio\u011flu S, Atalay A. Carnitine deficiency in diabetes mellitus complications. J Diabetes Complications. 1999;13(5):251\u20133.","journal-title":"J Diabetes Complications"},{"issue":"5","key":"682_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.nutres.2012.03.010","volume":"32","author":"E Liepinsh","year":"2012","unstructured":"Liepinsh E, Skapare E, Vavers E, Konrade I, Strele I, Grinberga S, et al. High l-carnitine concentrations do not prevent late diabetic complications in type 1 and 2 diabetic patients. Nutr Res. 2012;32(5):320\u20137.","journal-title":"Nutr Res"},{"issue":"4","key":"682_CR28","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1152\/physrev.1983.63.4.1420","volume":"63","author":"J Bremer","year":"1983","unstructured":"Bremer J. Carnitine\u2013metabolism and functions. Physiol Rev. 1983;63(4):1420\u201380.","journal-title":"Physiol Rev"},{"issue":"7","key":"682_CR29","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2174\/138920011796504536","volume":"12","author":"J Pekala","year":"2011","unstructured":"Pekala J, Patkowska-Sokola B, Bodkowski R, Jamroz D, Nowakowski P, Lochynski S, et al. L-Carnitine - Metabolic functions and meaning in humans life. Curr Drug Metab. 2011;12(7):667\u201378.","journal-title":"Curr Drug Metab"},{"issue":"1","key":"682_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/metabo11010051","volume":"11","author":"MR McCann","year":"2021","unstructured":"McCann MR, De la Rosa G, Rosania MV, Stringer GR. L-Carnitine and acylcarnitines: mitochondrial biomarkers for precision medicine. Metabolites. 2021;11(1):51.","journal-title":"Metabolites"},{"key":"682_CR31","doi-asserted-by":"publisher","first-page":"834205","DOI":"10.3389\/fendo.2022.834205","volume":"13","author":"WY Wang","year":"2022","unstructured":"Wang WY, Liu X, Gao XQ, Li X, Fang ZZ. Relationship between acylcarnitine and the risk of retinopathy in type 2 diabetes mellitus. Front Endocrinol. 2022;13:834205.","journal-title":"Front Endocrinol"},{"issue":"10","key":"682_CR32","doi-asserted-by":"publisher","first-page":"e0241365","DOI":"10.1371\/journal.pone.0241365","volume":"15","author":"JH Yun","year":"2020","unstructured":"Yun JH, Kim JM, Jeon HJ, Oh T, Choi HJ, Kim BJ. Metabolomics profiles associated with diabetic retinopathy in type 2 diabetes patients. PLoS ONE. 2020;15(10):e0241365.","journal-title":"PLoS ONE"},{"issue":"2\u20133","key":"682_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.brainresbull.2009.08.025","volume":"81","author":"RB Caldwell","year":"2010","unstructured":"Caldwell RB, Zhang W, Romero MJ, Caldwell RW. Vascular dysfunction in retinopathy-an emerging role for arginase. Brain Res Bull. 2010;81(2\u20133):303\u20139.","journal-title":"Brain Res Bull"},{"issue":"1","key":"682_CR34","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1172\/JCI116979","volume":"93","author":"S Roy","year":"1994","unstructured":"Roy S, Maiello M, Lorenzi M. Increased expression of basement membrane collagen in human diabetic retinopathy. J Clin Invest. 1994;93(1):438\u201342.","journal-title":"J Clin Invest"},{"key":"682_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.exer.2015.04.004","volume":"142","author":"S Roy","year":"2016","unstructured":"Roy S, Amin S, Roy S. Retinal fibrosis in diabetic retinopathy. Exp Eye Res. 2016;142:71\u20135.","journal-title":"Exp Eye Res"},{"issue":"12","key":"682_CR36","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s00726-021-02981-1","volume":"53","author":"J Du","year":"2021","unstructured":"Du J, Zhu S, Lim RR, Chao JR. Proline metabolism and transport in retinal health and disease. Amino Acids. 2021;53(12):1789\u2013806.","journal-title":"Amino Acids"},{"issue":"13","key":"682_CR37","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1177\/15353702221087175","volume":"247","author":"HA Resnikoff","year":"2022","unstructured":"Resnikoff HA, Miller CG, Schwarzbauer JE. Implications of fibrotic extracellular matrix in diabetic retinopathy. Exp Biol Med. 2022;247(13):1093\u2013102.","journal-title":"Exp Biol Med"},{"issue":"3\u20134","key":"682_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000363062","volume":"94","author":"Y Cao","year":"2014","unstructured":"Cao Y, Li X, Shi P, Wang L, xin. Sui Z Guo. Effects of L-carnitine on high glucose-induced oxidative stress in retinal ganglion cells. Pharmacology. 2014;94(3\u20134):123\u201330.","journal-title":"Pharmacology"},{"issue":"2","key":"682_CR39","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/jcm9020425","volume":"9","author":"E Shosha","year":"2020","unstructured":"Shosha E, Fouda AY, Narayanan SP, Caldwell RW, Caldwell RB. Is the arginase pathway a novel therapeutic avenue for diabetic retinopathy?? J Clin Med. 2020;9(2):425.","journal-title":"J Clin Med"},{"key":"682_CR40","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.preteyeres.2013.06.002","volume":"36","author":"SP Narayanan","year":"2013","unstructured":"Narayanan SP, Rojas M, Suwanpradid J, Toque HA, Caldwell RW, Caldwell RB. Arginase in retinopathy. Prog Retin Eye Res. 2013;36:260\u201380.","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"682_CR41","doi-asserted-by":"publisher","first-page":"e0268451","DOI":"10.1371\/journal.pone.0268451","volume":"17","author":"Y Li","year":"2022","unstructured":"Li Y, Gappy S, Liu X, Sassalos T, Zhou T, Hsu A, et al. Metformin suppresses pro-inflammatory cytokines in vitreous of diabetes patients and human retinal vascular endothelium. PLoS ONE. 2022;17(7):e0268451.","journal-title":"PLoS ONE"},{"key":"682_CR42","doi-asserted-by":"publisher","unstructured":"Zou AL, He T, Chen J, Sun X, Fan D. X, Rescue of Retinal Degeneration in rd1 Mice by Intravitreally Injected Metformin. Front Mol Neurosci. 2019 Apr 26 [cited 2024 Oct 13];12. Available from: https:\/\/www.frontiersin.org\/journals\/molecular-neuroscience\/articles\/https:\/\/doi.org\/10.3389\/fnmol.2019.00102\/full","DOI":"10.3389\/fnmol.2019.00102\/full"},{"issue":"4","key":"682_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/15353702211069986","volume":"247","author":"SV Amin","year":"2022","unstructured":"Amin SV, Khanna S, Parvar SP, Shaw LT, Dao D, Hariprasad SM, et al. Metformin and retinal diseases in preclinical and clinical studies: insights and review of literature. Exp Biol Med. 2022;247(4):317\u201329.","journal-title":"Exp Biol Med"},{"issue":"17","key":"682_CR44","doi-asserted-by":"publisher","first-page":"9453","DOI":"10.3390\/ijms22179453","volume":"22","author":"SK Hsu","year":"2021","unstructured":"Hsu SK, Cheng KC, Mgbeahuruike MO, Lin YH, Wu CY, Wang HMD, et al. New insight into the effects of Metformin on diabetic retinopathy, aging and cancer: nonapoptotic cell death, immunosuppression, and effects beyond the AMPK pathway. Int J Mol Sci. 2021;22(17):9453.","journal-title":"Int J Mol Sci"},{"key":"682_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.freeradbiomed.2023.05.019","volume":"205","author":"K Zhang","year":"2023","unstructured":"Zhang K, Wang T, Sun GF, Xiao JX, Jiang LP, Tou FF, et al. Metformin protects against retinal ischemia\/reperfusion injury through AMPK-mediated mitochondrial fusion. Free Radic Biol Med. 2023;205:47\u201361.","journal-title":"Free Radic Biol Med"},{"issue":"9","key":"682_CR46","first-page":"3947","volume":"8","author":"QY Yi","year":"2016","unstructured":"Yi QY, Deng G, Chen N, Bai ZS, Yuan JS, Wu GH, et al. Metformin inhibits development of diabetic retinopathy through inducing alternative splicing of VEGF-A. Am J Transl Res. 2016;8(9):3947\u201354.","journal-title":"Am J Transl Res"},{"issue":"1","key":"682_CR47","first-page":"2801450","volume":"2018","author":"Y Li","year":"2018","unstructured":"Li Y, Ryu C, Munie M, Noorulla S, Rana S, Edwards P, et al. Association of Metformin treatment with reduced severity of diabetic retinopathy in type 2 diabetic patients. J Diabetes Res. 2018;2018(1):2801450.","journal-title":"J Diabetes Res"},{"issue":"1","key":"682_CR48","first-page":"9161039","volume":"2020","author":"YP Fan","year":"2020","unstructured":"Fan YP, Wu CT, Lin JL, Hsiung CA, Liu HY, Lai JN, et al. Metformin treatment is associated with a decreased risk of nonproliferative diabetic retinopathy in patients with type 2 diabetes mellitus: A Population-Based cohort study. J Diabetes Res. 2020;2020(1):9161039.","journal-title":"J Diabetes Res"},{"key":"682_CR49","doi-asserted-by":"publisher","first-page":"109821","DOI":"10.1016\/j.diabres.2022.109821","volume":"186","author":"J Gerardo Gonz\u00e1lez-Gonz\u00e1lez","year":"2022","unstructured":"Gerardo Gonz\u00e1lez-Gonz\u00e1lez J, Cesar Solis R, D\u00edaz Gonz\u00e1lez-Colmenero A, Raygoza-Cortez K, Moreno-Pe\u00f1a PJ, S\u00e1nchez AL, et al. Effect of Metformin on microvascular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2022;186:109821.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"682_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/00006982-200001000-00008","volume":"20","author":"J Yepez","year":"2000","unstructured":"Yepez J, De JC, Arevalo JF. Topical Anesthesia In Posterior Vitrectomy. Retina. 2000;20(1):41.","journal-title":"RETINA"},{"key":"682_CR51","doi-asserted-by":"publisher","first-page":"105115","DOI":"10.1016\/j.phrs.2020.105115","volume":"161","author":"M Rudraraju","year":"2020","unstructured":"Rudraraju M, Narayanan SP, Somanath PR. Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy. Pharmacol Res. 2020;161:105115.","journal-title":"Pharmacol Res"},{"issue":"Supplement2","key":"682_CR52","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.2337\/diab.46.2.S26","volume":"46","author":"A Pfeiffer","year":"1997","unstructured":"Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Growth factor alterations in advanced diabetic retinopathy: A possible role of blood retina barrier breakdown. Diabetes. 1997;46(Supplement_2):S26\u201330.","journal-title":"Diabetes"},{"issue":"5","key":"682_CR53","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1089\/ars.2011.3906","volume":"15","author":"T Frey","year":"2011","unstructured":"Frey T, Antonetti DA. Alterations to the Blood\u2013Retinal barrier in diabetes: cytokines and reactive oxygen species. Antioxid Redox Signal. 2011;15(5):1271\u201384.","journal-title":"Antioxid Redox Signal"},{"issue":"10","key":"682_CR54","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1001\/archopht.1992.01080220134035","volume":"110","author":"J Sebag","year":"1992","unstructured":"Sebag J, Buckingham B, Charles MA, Reiser K. Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. Arch Ophthalmol. 1992;110(10):1472\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"682_CR55","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1021\/pr800112g","volume":"7","author":"BB Gao","year":"2008","unstructured":"Gao BB, Chen X, Timothy N, Aiello LP, Feener EP. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res. 2008;7(6):2516\u201325.","journal-title":"J Proteome Res"},{"issue":"1","key":"682_CR56","first-page":"582060","volume":"2015","author":"F Semeraro","year":"2015","unstructured":"Semeraro F, Cancarini A, dell\u2019Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res. 2015;2015(1):582060.","journal-title":"J Diabetes Res"},{"issue":"1","key":"682_CR57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/0301-4738.151464","volume":"63","author":"VV Chernykh","year":"2015","unstructured":"Chernykh VV, Varvarinsky EV, Smirnov EV, Chernykh DV, Trunov AN. Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy. Indian J Ophthalmol. 2015;63(1):33.","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"682_CR58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00125-020-05309-y","volume":"64","author":"Y Tomita","year":"2021","unstructured":"Tomita Y, Cagnone G, Fu Z, Cakir B, Kotoda Y, Asakage M, et al. Vitreous metabolomics profiling of proliferative diabetic retinopathy. Diabetologia. 2021;64(1):70\u201382.","journal-title":"Diabetologia"},{"issue":"2","key":"682_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/iovs.63.2.17","volume":"63","author":"H Wang","year":"2022","unstructured":"Wang H, Li S, Wang C, Wang Y, Fang J, Liu K. Plasma and vitreous metabolomics profiling of proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2022;63(2):17.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"682_CR60","doi-asserted-by":"publisher","first-page":"e14164","DOI":"10.1111\/acel.14164","volume":"23","author":"CHE Lau","year":"2024","unstructured":"Lau CHE, Manou M, Markozannes G, Ala-Korpela M, Ben-Shlomo Y, Chaturvedi N, et al. NMR metabolomic modeling of age and lifespan: A multicohort analysis. Aging Cell. 2024;23(7):e14164.","journal-title":"Aging Cell"},{"issue":"24","key":"682_CR61","doi-asserted-by":"publisher","first-page":"8656","DOI":"10.3390\/molecules27248656","volume":"27","author":"A Castro","year":"2022","unstructured":"Castro A, Signini \u00c9F, De Oliveira JM, Di Medeiros Leal MCB, Rehder-Santos P, Millan-Mattos JC, et al. The aging process: A metabolomics perspective. Molecules. 2022;27(24):8656.","journal-title":"Molecules"},{"issue":"12","key":"682_CR62","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1210\/jc.2018-01165","volume":"103","author":"LM \u2018t Hart","year":"2018","unstructured":"\u2018t Hart LM, Vogelzangs N, Mook-Kanamori DO, Brahimaj A, Nano J, van der Heijden AAWA, et al. Blood metabolomic measures associate with present and future glycemic control in type 2 diabetes. J Clin Endocrinol Metab. 2018;103(12):4569\u201379.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"682_CR63","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11306-020-01700-3","volume":"16","author":"EA Zelentsova","year":"2020","unstructured":"Zelentsova EA, Yanshole LV, Melnikov AD, Kudryavtsev IS, Novoselov VP, Tsentalovich YP. Post-mortem changes in metabolomic profiles of human serum, aqueous humor and vitreous humor. Metabolomics. 2020;16(7):80.","journal-title":"Metabolomics"},{"key":"682_CR64","doi-asserted-by":"publisher","unstructured":"Lillo A, Marin S, Serrano-Mar\u00edn J, Binetti N, Navarro G, Cascante M et al. Targeted Metabolomics Shows That the Level of Glutamine, Kynurenine, Acyl-Carnitines and Lysophosphatidylcholines Is Significantly Increased in the Aqueous Humor of Glaucoma Patients. Front Med. 2022 Jul 22 [cited 2025 Apr 23];9. Available from: https:\/\/www.frontiersin.orghttps:\/\/www.frontiersin.org\/journals\/medicine\/articles\/https:\/\/doi.org\/10.3389\/fmed.2022.935084\/full","DOI":"10.3389\/fmed.2022.935084\/full"},{"key":"682_CR65","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jpba.2019.06.013","volume":"174","author":"H Jin","year":"2019","unstructured":"Jin H, Zhu B, Liu X, Jin J, Zou H. Metabolic characterization of diabetic retinopathy: an 1H-NMR-based metabolomic approach using human aqueous humor. J Pharm Biomed Anal. 2019;174:414\u201321.","journal-title":"J Pharm Biomed Anal"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00682-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00682-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00682-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:03:23Z","timestamp":1747911803000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00682-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00682-5","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Provided in the Patients and Methods section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.C.M.: Bayer (consultant), Novartis (consultant), Roche (consultant), Apellis (consultant), and SJJ Solutions (consultant, patent share).G.P.: AbbVie (consultant), Bulbitech (consultant), Profundus (consultant), RetinaRISK (consultant), and Roche (consultant).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}